Sight Sciences, Inc. (SGHT) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript

Sight Sciences highlighted two payer wins for reimbursed procedural dry eye, with MACs Novitas and First Coast establishing fee schedules for TearCare in mid-October. Management said it has a strong balance sheet to fund commercial growth and selective investments while scaling both the TearCare dry eye business and the OMNI glaucoma franchise. The update is strategically positive, but it is mostly a conference presentation rather than a new financial disclosure.

Analysis

The key takeaway is not the product announcements themselves, but the proof-point they create for reimbursement as a sales-force multiplier. Once a procedure becomes payable, adoption typically shifts from physician enthusiasm to scheduler economics, which can shorten conversion cycles and improve utilization at existing account density; that is structurally more valuable than incremental device placement. The market is likely still underestimating how much of SGHT’s upside can come from better monetization of the same installed base rather than from a purely new-customer growth story.

The second-order effect is competitive: reimbursed dry eye creates a new standard that could pressure legacy in-office therapies, OTC-heavy solutions, and non-procedural product vendors that rely on patient self-pay friction. If MAC coverage expands beyond the current foothold, the category can move from a boutique procedure to a reimbursable workflow, which tends to re-rank winners toward companies with stronger field execution and gross margin leverage. That favors SGHT if management can prove repeatable site-level economics, but it also raises the bar for evidence generation and payer expansion cadence.

The main risk is that early reimbursement wins are mistaken for broad market access. MAC coverage is a localized catalyst, not a national reset, so the next 2-3 quarters likely matter more for operating metrics than headline narrative: utilization per account, procedure frequency, and incremental sales efficiency will tell us whether this is scaling or just a pilot. A slower-than-expected payer rollout or weak physician pull-through would quickly compress the multiple because the stock is already leaning on the optionality of a new reimbursed category.

Contrarian angle: consensus may be focusing too much on TearCare as the near-term inflection and not enough on OMNI as the cash-generative engine that funds the dry-eye buildout. If glaucoma momentum continues while dry-eye reimbursement expands gradually, SGHT could re-rate on durability rather than hypergrowth, which is often a better setup for multiple expansion in medtech. The best risk/reward is likely in waiting for evidence of sustained reimbursement-driven volume, then buying into a de-risked execution story rather than into the initial announcement spike.

Key Decisions for Investors

• Long SGHT on weakness over the next 1-3 weeks: use pullbacks toward post-conference support to build a starter position, targeting a 6-9 month re-rating if reimbursement converts into measurable procedure growth; risk is a quick fade if MAC coverage proves non-scalable.
• Sell out-of-the-money SGHT calls or run a call spread into the next 4-8 weeks: monetize event-driven premium while the market digests the reimbursement narrative; this caps upside if management delivers another payer update sooner than expected.
• Pair trade: long SGHT / short a broad medtech or eye-care peer basket over 3-6 months, expressing relative upside from reimbursement monetization while hedging sector beta; thesis works if SGHT shows better revenue acceleration from same-account utilization.
• Monitor for a second MAC or commercial payer announcement over the next 1-2 quarters; if absent, reduce exposure, as the equity case likely depends on visible expansion beyond the initial fee schedules.
• If you want lower-risk exposure, wait for evidence of sustained quarterly procedure growth before adding aggressively; upside remains meaningful, but the current setup is better suited to staged accumulation than full-size entry.